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Changes in expression of transforming growth factor
beta mRNA isoforms in patients undergoing tamoxifen
therapy
Reply to the letter from Benson and Colletta
Sir
The controversy surrounding the complex role of transforming
growth factor (TGF-P) in breast cancer is once again highlighted
in the letter of Mr JR Benson and Dr AA Colletta. The comments
made are informative and, while we would concur with many of
them, we feel that some additional response is appropriate to
clarify some ofthe issues raised.
First of all, it is important to emphasize that the aim of our study
was to determine the effect of tamoxifen on TGF-P expression in
breast cancers from patients whose tumours could be accurately
assessed for response to therapy. It was not a study to elucidate the
role ofTGF-P in carcinogenesis or to assess expression in different
stages of disease, although we have already published data on the
latter (MacCallum et al, 1994). Although the study is limited to a
definedgroupofpatients,this is an importantcohort,andone inwhich
we could obtain sequential samples of tumour and accurately assess
response of these same lesions to tamoxifen treatment (Incidentally,
the rationale forusing ultrasound as an accurate assessment oftumour
size has already been published by Forouhi et al, 1994).
Secondly, we believe we have correctly shown conservatism in
terms of attributing differences between sequential samples of the
same tumour to the effects oftamoxifen. It is essential that inherent
variations of methodology and tumour heterogeneity are assessed
and realistically taken into account. Having done this in the present
study, it was reassuring that, with regard toTGF-P2 not only was it
more likely for expression to be higher in tamoxifen-treated biop-
sies but also that this pattern was exclusive to responding tumours.
We have therefore been satisfied that these effects were mediated
by tamoxifen. However, the direction of effects of treatment on
TGF-f 1 were almost equally increases or decreases, and there was
no statistical difference in patterns between responders and non-
responders. We have therefore been reluctant to claim dogmati-
cally that these influences are caused by tamoxifen, despite a
degree ofchange exceeding that ofour controls.
Nevertheless, we have discussed the possibility that tamoxifen
might more commonly induce the expression of TGF-,B1 in breast
cancers, an effect which may not have been apparent in our study
fora variety ofreasons (MacCallum et al, 1996). The exhaustion of
stromal induction ofTGF-P, as suggested by JR Benson and AA
Colletta, is also possible. However, that the stroma is the primary
source ofTGF-P is controversial; both we and others have shown
thatTGF-P appears to be synthesized predominantly within epithe-
lial cells of breast cancers (Auvinen et al, 1995; MacCallum et al,
1995; Walker and Gallagher, 1995). This is not necessarily at odds
with the apparent increased staining of TGF-,B1 in stroma
following primary tamoxifen therapy, as reported by Butta et al
(1992), if the growth factor was synthesized and secreted by
epithelial cells, but sequestered by the stromal compartment.
Indeed, if tamoxifen causes the death of epithelial cells, there
might be an impression of upregulation in residual stroma. We
would agree however, that simultaneous measurements of TGF-,
protein and mRNA would give an additional dimension to these
studies. Our immunohistochemical investigations are currently
under way, and preliminary data suggest that both TGF-P1 and
TGF-P2 predominantly localize to the epithelium.
In vitro studies using cell lines and animal models have yielded
important understanding ofthe role ofTGF-P in breast cancer, but
ultimately it is necessary to look at appropriate clinical material.
Such translational studies can be difficult to perform and may
produce results that are subject to variable interpretation depending
on perspective. However, in carrying out the reported study, we
believe that we have not only generated meaningful results, but
have been objective in deriving our conclusions.
J MacCallum and WR Miller
ICRFMedical Oncology Unit, Western General Hospital
Edinburgh EH4 2XU, UK
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Nuclear Oncology: From Genotype to Patient Care
Thomas B. Turner Building,Baltimore, Maryland
Sponsor:
Johns Hopkins University School of Medicine
Course director:
Henry N. Wagner Jr, MD
Nuclear medicine is the medical specialty best suited to translate
the exploding body of knowledge obtained from research in
genetics and molecular biology into the care of patients. This
fourth annual nuclear oncology conference will address how this
can be done and how positron emission tomography (PET) and
single photon emission tomography (SPECT) can detect the first
signs of disease in patients with increased genetic risk of devel-
oping cancer. The course will include illustrative patient studies,
showing how PET and SPECT can help diagnosis, staging and
treatment planning and monitoring.
The Johns Hopkins University School of Medicine is accredited
by the Accreditaion Council for Continuing Medical Education to
sponsor continuing medical education for physicians.
The Johns Hopkins University designates this continuing
medical education activity for up to 18 credit hours in Category 1
of the Physician's Recognition Award of the American Medical
Association.
Fee:
Physicians: $495; Residents, Fellows and Allied Health
Professionals: $395
Contactperson:
Program Coordinator, Johns Hopkins Medical Institutions, Office
ofContinuing Medical Education, Turner Building, 720 Rutland
Avenue, Baltimore, Maryland 21205
Tel: (410) 955 2959
Fax: (410) 955 0807
Internet: rturner@somr.admjhu.edu
or Julia W. Buchanan, Course Co-director,
Tel: (410) 955-8582
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